Youcare Pharmaceutical Group (688658) Fundamentals 2026 — Revenue Analysis | SniperIQ
Youcare Pharmaceutical Group (688658) is a CN-listed Healthcare company in Biotechnology with a market capitalization of ¥5.7B, trading at ¥12.72 on the SHH. This SniperIQ fundamentals page covers Youcare Pharmaceutical Group's valuation, profitability (net margin -10.2%), revenue (¥2.4B in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is Youcare Pharmaceutical Group's market cap?
Youcare Pharmaceutical Group (688658) has a market capitalization of approximately ¥5.7B, trading at ¥12.72 on the SHH. Market cap moves with the live share price.
What is Youcare Pharmaceutical Group's P/E ratio?
Youcare Pharmaceutical Group's trailing twelve-month P/E ratio is not meaningful (negative or nil earnings), with a price-to-book (P/B) of 1.8x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is Youcare Pharmaceutical Group?
Youcare Pharmaceutical Group runs a net profit margin of -10.2%, a gross margin of 103.3%, and an operating margin of -8.1%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does Youcare Pharmaceutical Group generate?
Youcare Pharmaceutical Group reported revenue of ¥2.4B for fiscal year 2025, with net income of -¥262M and earnings per share (EPS) of -0.59. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does Youcare Pharmaceutical Group pay a dividend?
Youcare Pharmaceutical Group does not currently show a material trailing dividend yield; it is positioned more as a total-return name. Always confirm the latest dividend policy in the company's filings.
Is Youcare Pharmaceutical Group financially healthy?
Youcare Pharmaceutical Group carries a debt-to-equity ratio of 0.17x and a current ratio of 1.97x, with a market beta of 0.64. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is Youcare Pharmaceutical Group a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Youcare Pharmaceutical Group (688658) the key facts are: market cap ¥5.7B, revenue ¥2.4B, 52-week range 12-36.49. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.
Track Youcare Pharmaceutical Group's full fundamentals live
Get Youcare Pharmaceutical Group's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.